首页> 外文期刊>International Journal of Molecular Sciences >Extracellular MicroRNAs in Urologic Malignancies: Chances and Challenges
【24h】

Extracellular MicroRNAs in Urologic Malignancies: Chances and Challenges

机译:泌尿系恶性肿瘤中的细胞外MicroRNA:机会和挑战

获取原文
获取外文期刊封面目录资料

摘要

Small noncoding RNAs that are 19–23 nucleotides long, known as microRNAs (miRNAs), are involved in almost all biological mechanisms during carcinogenesis. Recent studies show that miRNAs released from live cells are detectable in body fluids and may be taken up by other cells to confer cell-cell communication. These released miRNAs (here referred to as extracellular miRNAs) are often protected by RNA-binding proteins or embedded inside circulating microvesicles. Due to their relative stability, extracellular miRNAs are believed to be promising candidates as biomarkers for diagnosis and prognosis of disease, or even as therapeutic agents for targeted treatment. In this review, we first describe biogenesis and characteristics of these miRNAs. We then summarize recent publications involving extracellular miRNA profiling studies in three representative urologic cancers, including: prostate cancer, bladder cancer, and renal cell carcinoma. We focus on the diagnostic, prognostic, and therapeutic potential of these miRNAs in biological fluids, such as serum, plasma, and urine. Finally, we discuss advantages and challenges of these miRNAs in clinical applications.
机译:长度为19-23个核苷酸的小型非编码RNA(称为microRNA(miRNA))几乎参与了癌变过程中的所有生物学机制。最近的研究表明,从活细胞释放的miRNA在体液中是可检测的,并且可能被其他细胞吸收以赋予细胞与细胞之间的通讯。这些释放的miRNA(此处称为细胞外miRNA)通常受到RNA结合蛋白的保护或嵌入循环微泡内部。由于它们的相对稳定性,细胞外miRNA被认为是有望用于疾病诊断和预后的生物标志物,甚至是用于靶向治疗的治疗剂。在这篇综述中,我们首先描述了这些miRNA的生物发生和特征。然后,我们总结了涉及三种代表性泌尿科癌症的有关细胞外miRNA分析研究的最新出版物,包括:前列腺癌,膀胱癌和肾细胞癌。我们专注于这些miRNA在血清,血浆和尿液等生物体液中的诊断,预后和治疗潜力。最后,我们讨论了这些miRNA在临床应用中的优势和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号